ArticleCancers2018
Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.
Article in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.The Lancet. Haematology · 2020Trial
- Tumoricidal potential of binary therapy in lymphoma: Role of DC-NK cross-talk and checkpoint inhibitors.Histology and histopathology · 2025Review
- SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study.Cells · 2024Article
- TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background.Oncogene · 2023Article
- PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion.Haematologica · 2023Article
- Checkpoint inhibition in hematologic malignancies.Frontiers in oncology · 2023Review
- High percentages of peripheral blood T-cell activation in childhood Hodgkin's lymphoma are associated with inferior outcome.Frontiers in medicine · 2022Article
- Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency.Frontiers in immunology · 2022Article
- Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.Haematologica · 2022Article
- Transcriptomic profiling in canines and humans reveals cancer specific gene modules and biological mechanisms common to both species.PLoS computational biology · 2021Article
- Immunotherapies in Non-Hodgkin's Lymphoma.Cancers · 2021Article
- Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms.BioMed research international · 2021Article
- Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches.International journal of molecular sciences · 2020Review
- Targeting immune checkpoints in hematological malignancies.Journal of hematology & oncology · 2020Review
- Inflammatory Cells in Diffuse Large B Cell Lymphoma.Journal of clinical medicine · 2020Review
- Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application.Cancers · 2019Review
- Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It.International journal of molecular sciences · 2019Review
- Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis.Frontiers in oncology · 2019Article
- Immune targeting of the microenvironment in classical Hodgkin's lymphoma: insights for the hematologist.Therapeutic advances in hematology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic blockade of PD-1/PD-L1 shows promising results in Hodgkin's lymphoma (HL) and in some diffuse large B-cell lymphoma (DLBCL) patients, but biomarkers predicting such responses are still lacking. To this end, we recently developed a transcriptional scoring of immune escape (IE) in cancer biopsies. Using this method in DLBCL, we identified four stages of IE correlated with overall survival, but whether Hodgkin's lymphomas (HL) also display this partition was unknown. Thus, we explored the transcriptomic profiles of ~1000 HL and DLBCL using a comparative meta-analysis of their bulk microarrays. Relative to DLBCL, the HL co-clustered at the advanced stage of immune escape, displaying significant enrichment of both IE and T-cell activation genes. Analyses via transcriptome deconvolution and immunohistochemistry showed more CD3⁺ and CD4⁺ tumor-infiltrating lymphocytes (TILs) in HL than DLBCL. Both HL and non-GCB DLBCL shared a high abundance of infiltrating CD8⁺ T-cells, but HL had less CD68⁺CD163⁺ macrophages. The same cellular distribution of PD-1 and TIM-3 was observed in HL and DLBCL, though HL had more PD-L1 tumor cells and LAG-3 ME cells. This study illuminates the advanced stage of immune activation and escape in HL, consistent with the response to checkpoint blockade therapies for this type of lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.